Sunshine Biopharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Sunshine Biopharma Inc. (SBFM)
NASDAQ:AMEX Investor Relations:
sunshinebiopharma.com/press-releases.html
Company Research
Source: Yahoo! Finance
Net loss: US$4.51m (loss narrowed by 83% from FY 2022). US$0.18 loss per share (improved from US$1.76 loss in FY 2022). All figures shown in the chart above are for the trailing 12 month (TTM) period Sunshine Biopharma Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) missed analyst estimates by 19%. Looking ahead, revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 2.5% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 3 warning signs for Sunshine Biopharma you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide comme
Show less
Read more
Impact Snapshot
Event Time:
SBFM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SBFM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SBFM alerts
High impacting Sunshine Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
SBFM
News
- NORA PHARMA RECEIVES HEALTH CANADA APPROVAL FOR NIOPEG®, A BIOSIMILAR OF NEULASTA® [Yahoo! Finance]Yahoo! Finance
- NORA PHARMA RECEIVES HEALTH CANADA APPROVAL FOR NIOPEG®, A BIOSIMILAR OF NEULASTA®PR Web
- Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers [Seeking Alpha]Seeking Alpha
- Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) [Yahoo! Finance]Yahoo! Finance
- Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)Accesswire
SBFM
Sec Filings
- 5/6/24 - Form 8-K
- 4/23/24 - Form 8-K
- 4/1/24 - Form 8-K
- SBFM's page on the SEC website